<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088452</url>
  </required_header>
  <id_info>
    <org_study_id>U01NS045911</org_study_id>
    <secondary_id>U01NS045803</secondary_id>
    <nct_id>NCT00088452</nct_id>
  </id_info>
  <brief_title>Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study</brief_title>
  <official_title>Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the best initial treatment for childhood absence&#xD;
      epilepsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Childhood absence epilepsy (CAE) is a common pediatric epilepsy syndrome that affects 10 to&#xD;
      15 percent of all children with epilepsy. Individuals with CAE have brief staring spell&#xD;
      seizures that occur suddenly, unpredictably, and frequently throughout the day. These&#xD;
      seizures impair the children's ability to learn and play, and lead to higher injury rates.&#xD;
&#xD;
      There are many medications used to treat seizures, but only 3 generally are used as the first&#xD;
      treatment for children with CAE: ethosuximide, lamotrigine, and valproic acid. The goal of&#xD;
      this study is to determine which of these 3 medicines is the best first choice as treatment&#xD;
      for children with CAE.&#xD;
&#xD;
      Approximately 439 children, recruited over a 3-year period at 32 medical centers in the US,&#xD;
      will take part in this 5-year study. Participants will be randomly given one of the 3 common&#xD;
      CAE treatments-ethosuximide, lamotrigine, or valproic acid-and will make regular visits to a&#xD;
      clinic every 1 to 3 months for approximately 2 years. During the visits, participants will&#xD;
      undergo regular testing to determine if the medicine is working, to watch for side effects,&#xD;
      and to help researchers learn more about the responses to these medicines. In addition,&#xD;
      researchers hope to develop methods that may be used in the future to help choose the best&#xD;
      medicine for each individual diagnosed with CAE.&#xD;
&#xD;
      Also included in the study will be pharmacokinetics and pharmacogenetics research.&#xD;
      Pharmacokinetics is the study of how the body absorbs, distributes, metabolizes, and excretes&#xD;
      drugs. Pharmacogenetics is the study of genetic determinants of the response to drugs.&#xD;
      Knowledge gained from this study may lead to individualized treatment for children with CAE,&#xD;
      and may also be beneficial for other pediatric and adult seizure disorders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2004</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy</measure>
    <time_frame>First 16-20 weeks of double blind therapy</time_frame>
    <description>Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT</measure>
    <time_frame>First 16-20 weeks of double blind therapy</time_frame>
    <description>A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy</measure>
    <time_frame>First 12 months of double blind therapy</time_frame>
    <description>Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">453</enrollment>
  <condition>Childhood Absence Epilepsy</condition>
  <condition>Petit Mal Epilepsy</condition>
  <condition>Epilepsy</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Ethosuximide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ethosuximide&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup&#xD;
Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamotrigine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lamotrigine&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets&#xD;
Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valproic acid&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.&#xD;
Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethosuximide</intervention_name>
    <description>Ethosuximide is a common treatment for childhood absence epilepsy.</description>
    <arm_group_label>Ethosuximide</arm_group_label>
    <other_name>Zarontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Lamotrigine is a common treatment for childhood absence epilepsy.</description>
    <arm_group_label>Lamotrigine</arm_group_label>
    <other_name>Lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic acid</intervention_name>
    <description>Valproic acid is a common treatment for childhood absence epilepsy.</description>
    <arm_group_label>Valproic acid</arm_group_label>
    <other_name>Depakote</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis: Clinical diagnosis of Childhood Absence Epilepsy consistent with the&#xD;
             International League against Epilepsy Proposal for Revised Classification of&#xD;
             Epilepsies and Epileptic Syndromes (3).&#xD;
&#xD;
          -  EEG: Interictal EEG demonstrating bilateral synchronous symmetrical approximate 3 Hz&#xD;
             spike waves on a normal background with at least one burst lasting &gt;/= (greater than&#xD;
             or equal to) 3 seconds.&#xD;
&#xD;
          -  Age &gt; 2.5 years and &lt; 13 years of age at study entry.&#xD;
&#xD;
          -  Body weight &gt;/= (greater than or equal to) 10 kilograms.&#xD;
&#xD;
          -  Body Mass Index: BMI for age =/&lt; 99th percentile (based on the CDC BMI for age growth&#xD;
             curves for boys/girls [http://www.cdc.gov/growthcharts], Appendix 1).&#xD;
&#xD;
          -  Hepatic:&#xD;
&#xD;
          -  AST/ALT &lt; 2.5 times the upper limit of normal&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times the upper limit of normal.&#xD;
&#xD;
          -  Hematologic:&#xD;
&#xD;
          -  Absolute neutrophil count &gt;/= (greater than or equal to) 1500/mm3.&#xD;
&#xD;
          -  Platelets &gt;/= (greater than or equal to) 120, 000 /mm3.&#xD;
&#xD;
          -  Female subjects must be premenarchal at the time of enrollment and must be willing to&#xD;
             practice abstinence for the duration of the study.&#xD;
&#xD;
          -  Parent/legal guardian(s) willing to sign an IRB approved informed consent.&#xD;
&#xD;
          -  Subject assent (when appropriate and as dictated by local IRB).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment for CAE with anti-seizure medications (AED) for a period of greater than 7&#xD;
             days prior to randomization.&#xD;
&#xD;
          -  History of a major psychiatric disease (e.g., psychosis, major depression).&#xD;
&#xD;
          -  History of autism or pervasive development disorder.&#xD;
&#xD;
          -  History of non-febrile seizures other than typical absence seizures. This includes a&#xD;
             history of an afebrile generalized tonic clonic seizure.&#xD;
&#xD;
          -  Clinical signs and symptoms consistent with a diagnosis of juvenile absence epilepsy&#xD;
             or juvenile myoclonic epilepsy as delineated by the International League against&#xD;
             Epilepsy Proposal for Revised Classification of Epilepsies and Epileptic Syndromes&#xD;
             (3).&#xD;
&#xD;
          -  History of recent or present significant or medical disease, i.e., cardiovascular,&#xD;
             hepatic, renal, gynecologic, musculoskeletal, metabolic, or endocrine.&#xD;
&#xD;
          -  History of a severe dermatologic reaction (e.g., Stevens Johnson, toxic epidermolysis&#xD;
             necrosis) to medication.&#xD;
&#xD;
          -  Subject or parent/legal guardian might not be reasonably expected to be compliant with&#xD;
             or to complete the study.&#xD;
&#xD;
          -  Participation in a trial of an investigational drug or device within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Use of systemic contraceptive for any indication, including acne.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tracy A. Glauser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Adamson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avital Cnaan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mattel Children's Hospital at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Comprehensive Epilepsy Center, Manhattan</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies &amp; Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Inc., PCTI</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBonheur Children's Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Pediatric Neurology Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah/Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughter (Monarch Medical Research)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105-0371</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201-1997</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Adamson PC; Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013 Jan;54(1):141-55. doi: 10.1111/epi.12028. Epub 2012 Nov 21.</citation>
    <PMID>23167925</PMID>
  </reference>
  <reference>
    <citation>Cnaan A, Shinnar S, Arya R, Adamson PC, Clark PO, Dlugos D, Hirtz DG, Masur D, Glauser TA; Childhood Absence Epilepsy Study Group. Second monotherapy in childhood absence epilepsy. Neurology. 2017 Jan 10;88(2):182-190. doi: 10.1212/WNL.0000000000003480. Epub 2016 Dec 16.</citation>
    <PMID>27986874</PMID>
  </reference>
  <reference>
    <citation>Shinnar S, Cnaan A, Hu F, Clark P, Dlugos D, Hirtz DG, Masur D, Mizrahi EM, Mosh√© SL, Glauser TA; Childhood Absence Epilepsy Study Group. Long-term outcomes of generalized tonic-clonic seizures in a childhood absence epilepsy trial. Neurology. 2015 Sep 29;85(13):1108-14. doi: 10.1212/WNL.0000000000001971. Epub 2015 Aug 26.</citation>
    <PMID>26311751</PMID>
  </reference>
  <results_reference>
    <citation>Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9. doi: 10.1056/NEJMoa0902014.</citation>
    <PMID>20200383</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 26, 2004</study_first_submitted>
  <study_first_submitted_qc>July 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2004</study_first_posted>
  <results_first_submitted>August 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood absence epilepsy</keyword>
  <keyword>CAE</keyword>
  <keyword>petit mal epilepsy</keyword>
  <keyword>epilepsy</keyword>
  <keyword>seizures</keyword>
  <keyword>ethosuximide</keyword>
  <keyword>lamotrigine</keyword>
  <keyword>valproic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy, Absence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Ethosuximide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 18, 2005</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT00088452/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment occurred from July 2004 through October 2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ethosuximide</title>
          <description>Ethosuximide&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup&#xD;
Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)&#xD;
Ethosuximide: Ethosuximide is a common treatment for childhood absence epilepsy.</description>
        </group>
        <group group_id="P2">
          <title>Lamotrigine</title>
          <description>Lamotrigine&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets&#xD;
Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower).&#xD;
Lamotrigine: Lamotrigine is a common treatment for childhood absence epilepsy.</description>
        </group>
        <group group_id="P3">
          <title>Valproic Acid</title>
          <description>Valproic acid&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.&#xD;
Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)&#xD;
Valproic acid: Valproic acid is a common treatment for childhood absence epilepsy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ethosuximide</title>
          <description>Ethosuximide&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup&#xD;
Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)&#xD;
Ethosuximide: Ethosuximide is a common treatment for childhood absence epilepsy.</description>
        </group>
        <group group_id="B2">
          <title>Lamotrigine</title>
          <description>Lamotrigine&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets&#xD;
Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower).&#xD;
Lamotrigine: Lamotrigine is a common treatment for childhood absence epilepsy.</description>
        </group>
        <group group_id="B3">
          <title>Valproic Acid</title>
          <description>Valproic acid&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.&#xD;
Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)&#xD;
Valproic acid: Valproic acid is a common treatment for childhood absence epilepsy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="155"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="147"/>
            <count group_id="B4" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="451"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="258"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="334"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI &gt; 90th percentile for age</title>
          <description>BMI &gt; 90th percentile for age using the units of kg/m2</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy</title>
        <description>Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.</description>
        <time_frame>First 16-20 weeks of double blind therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ethosuximide</title>
            <description>Ethosuximide&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup&#xD;
Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)&#xD;
Ethosuximide: Ethosuximide is a common treatment for childhood absence epilepsy.</description>
          </group>
          <group group_id="O2">
            <title>Lamotrigine</title>
            <description>Lamotrigine&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets&#xD;
Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower).&#xD;
Lamotrigine: Lamotrigine is a common treatment for childhood absence epilepsy.</description>
          </group>
          <group group_id="O3">
            <title>Valproic Acid</title>
            <description>Valproic acid&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.&#xD;
Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)&#xD;
Valproic acid: Valproic acid is a common treatment for childhood absence epilepsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy</title>
          <description>Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculations of sample size were based on the ability to detect a 20% difference in freedom-from failure rates (three pairwise comparisons) at 16 weeks with 80% power at a two-sided P value of 0.017 and one interim analysis. Sample size of 398 was increased to 446 subjects to account for two stratification factors and a 5% dropout rate; this sample size allowed the detection of a difference of 0.5 SD in the Confidence Index on the Conners' Continuous Performance Test with a power exceeding 80%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
            <estimate_desc>odds ratio with ethosuximide vs. lamotrigine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Calculations of sample size were based on the ability to detect a 20% difference in freedom-from failure rates (three pairwise comparisons) at 16 weeks with 80% power at a two-sided P value of 0.017 and one interim analysis. Sample size of 398 was increased to 446 subjects to account for two stratification factors and a 5% dropout rate; this sample size allowed the detection of a difference of 0.5 SD in the Confidence Index on the Conners' Continuous Performance Test with a power exceeding 80%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.06</ci_lower_limit>
            <ci_upper_limit>5.42</ci_upper_limit>
            <estimate_desc>odds ratio with valproic acid vs. lamotrigine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT</title>
        <description>A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder.</description>
        <time_frame>First 16-20 weeks of double blind therapy</time_frame>
        <population>Those subject who took the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events).</population>
        <group_list>
          <group group_id="O1">
            <title>Ethosuximide</title>
            <description>Ethosuximide&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup&#xD;
Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)&#xD;
Ethosuximide: Ethosuximide is a common treatment for childhood absence epilepsy.</description>
          </group>
          <group group_id="O2">
            <title>Lamotrigine</title>
            <description>Lamotrigine&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets&#xD;
Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower).&#xD;
Lamotrigine: Lamotrigine is a common treatment for childhood absence epilepsy.</description>
          </group>
          <group group_id="O3">
            <title>Valproic Acid</title>
            <description>Valproic acid&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.&#xD;
Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)&#xD;
Valproic acid: Valproic acid is a common treatment for childhood absence epilepsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Attention Deficit as Measured by the Confidence Index of the CPT-II and the K-CPT</title>
          <description>A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder.</description>
          <population>Those subject who took the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
            <estimate_desc>Percentage of subjects with a Confidence Index score of 0.60 or higher in the valproic acid group than in the ethosuximide group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>5.49</ci_upper_limit>
            <estimate_desc>Percentage of subjects with a Confidence Index score of 0.60 or higher in the valproic acid group than in the lamotrigine group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy</title>
        <description>Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.</description>
        <time_frame>First 12 months of double blind therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ethosuximide</title>
            <description>Ethosuximide&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup&#xD;
Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)&#xD;
Ethosuximide: Ethosuximide is a common treatment for childhood absence epilepsy.</description>
          </group>
          <group group_id="O2">
            <title>Lamotrigine</title>
            <description>Lamotrigine&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets&#xD;
Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower).&#xD;
Lamotrigine: Lamotrigine is a common treatment for childhood absence epilepsy.</description>
          </group>
          <group group_id="O3">
            <title>Valproic Acid</title>
            <description>Valproic acid&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.&#xD;
Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)&#xD;
Valproic acid: Valproic acid is a common treatment for childhood absence epilepsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Treatment Failure at 12 Months of Double Blind Therapy</title>
          <description>Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.81</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
            <estimate_desc>Odds ratio for FFF for ethosuximide versus lamotrigine</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.68</ci_lower_limit>
            <ci_upper_limit>5.02</ci_upper_limit>
            <estimate_desc>odds ratio for FFF for valproic acid versus lamotrigine</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over 3.5 years</time_frame>
      <desc>The definition of adverse event and/or serious adverse event, used to collect adverse event information, is the same as clinicaltrials.gov defintions</desc>
      <group_list>
        <group group_id="E1">
          <title>Ethosuximide</title>
          <description>Ethosuximide&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight and ability to swallow): 250mg Zarontin capsules OR 250 mg/5 mL Zarontin syrup&#xD;
Dosing: Ethosuximide was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 2000 mg/day (whichever was lower)&#xD;
Ethosuximide: Ethosuximide is a common treatment for childhood absence epilepsy.</description>
        </group>
        <group group_id="E2">
          <title>Lamotrigine</title>
          <description>Lamotrigine&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Three formulations were used (actual formulation used was dependent on the patient's weight): 5mg Lamictal chewable tablets OR 25 mg Lamictal chewable tablets OR 25 mg (Lamictal tablets&#xD;
Dosing: Lamotrigine was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 12 mg/kg/day or 600 mg/day (whichever was lower).&#xD;
Lamotrigine: Lamotrigine is a common treatment for childhood absence epilepsy.</description>
        </group>
        <group group_id="E3">
          <title>Valproic Acid</title>
          <description>Valproic acid&#xD;
Frequency and Duration: twice a day, every day for the duration of the study treatment&#xD;
Formulation: Two formulations were used (actual formulation used was dependent on the patient's weight): 250mg Depakote capsules OR 125mg Depakote sprinkles.&#xD;
Dosing: Depakote was titrated in predetermined increments every 1-2 weeks during a 16-week titration period. The titration continued until the patient a) achieved seizure freedom by clinical and EEG criteria, b) reached the maximal allowed study drug dose, c) reached the maximal tolerated dose, or d) developed dose-exiting criteria (treatment failure), whichever came first. Maximum allowed dose: 60 mg/kg/day or 3000 mg/day (whichever was lower)&#xD;
Valproic acid: Valproic acid is a common treatment for childhood absence epilepsy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <description>Due to Salmonella poisoning</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized tonic clonic seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Prolonged Absence Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pneumonia, diarrhea, vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Non-epileptic movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Acting Out</sub_title>
                <description>Voluntarily committed</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="155"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, vomiting, or both</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="155"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Stomach upset</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="155"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="155"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="155"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Weight increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="155"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="149"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="155"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="149"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Sleep problem</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="155"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in concentration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="155"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Attentional difficulties</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="155"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Memory problems</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperactivity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="155"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This short-term study was not designed to detect long-term systemic or other cognitive effects of these three medications.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tracy Glauser, MD</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-636-8854</phone>
      <email>tracy.glauser@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

